Imatinib Zentiva (Imatinib)

Imatinib binds to the ATP‑binding pocket of the BCR‑ABL, KIT and PDGFR tyrosine kinases, preventing phosphorylation of downstream substrates. This blockade stops the proliferative signals that cancer cells rely on, leading to cell cycle arrest and apoptosis of the malignant clone.

The specific dose of Imatinib Zentiva is determined by the prescribing physician based on the patient’s diagnosis, disease stage, renal and hepatic function, and other clinical factors. The prescriber will tailor the regimen to achieve optimal therapeutic effect while minimizing toxicity.

The safety of Imatinib Zentiva in pregnancy and lactation has not been established. It is generally advised to avoid use during pregnancy unless the potential benefit outweighs the risk, and breastfeeding is not recommended because the drug can be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Imatinib was the first BCR‑ABL inhibitor approved and remains a standard of care for CML and Ph+ ALL. Newer agents such as dasatinib or nilotinib may offer potency against certain resistant mutations, but Imatinib retains a well‑characterized safety profile and is often preferred as first‑line therapy in many treatment guidelines.

Imatinib Zentiva should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Do not store in bathrooms or near heat sources, and keep the container tightly closed when not in use.

The medication is taken orally, usually once daily, with a glass of water. It can be swallowed whole with or without food; however, consistent intake with respect to meals helps maintain stable absorption. Patients should follow the prescriber’s instructions regarding timing and any required dose adjustments.

Serious adverse events include severe liver injury, profound neutropenia or thrombocytopenia, cardiac dysfunction, pulmonary arterial hypertension, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Prompt medical evaluation is essential if any of these symptoms arise.

Imatinib Zentiva is contraindicated in patients with known hypersensitivity to imatinib or any of its excipients. It should also be avoided in individuals with severe hepatic impairment unless dose adjustments are made, and it is not recommended for pregnant women unless absolutely necessary.